Intrathecal Injection of JWH-015 Attenuates Bone Cancer Pain Via Time-Dependent Modification of Pro-inflammatory Cytokines Expression and Astrocytes Activity in Spinal Cord

Inflammation ◽  
2015 ◽  
Vol 38 (5) ◽  
pp. 1880-1890 ◽  
Author(s):  
Cui’e Lu ◽  
Yue Liu ◽  
Bei Sun ◽  
Yu’e Sun ◽  
Bailing Hou ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Inflammatory Cytokines ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Time Dependent ◽  
Bone Cancer Pain ◽  
Dependent Modification ◽  
Pro Inflammatory Cytokines

scholarly journals Rosiglitazone Alleviates Mechanical Allodynia of Rats with Bone Cancer Pain through the Activation of PPAR-γ to Inhibit the NF-κB/NLRP3 Inflammatory Axis in Spinal Cord Neurons

PPAR Research ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-18
Author(s):  
Jie Fu ◽  
Baoxia Zhao ◽  
Chaobo Ni ◽  
Huadong Ni ◽  
Longsheng Xu ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Receptor Protein ◽  
Bone Cancer Pain ◽  
Dependent Manner ◽  
Concurrent Administration ◽  
Spinal Cord Neurons ◽  
Ppar Γ

Bone cancer pain (BCP) is a serious clinical problem that affects the quality of life of cancer patients. However, the current treatment methods for this condition are still unsatisfactory. This study investigated whether intrathecal injection of rosiglitazone modulates the noxious behaviors associated with BCP, and the possible mechanisms related to this effect were explored. We found that rosiglitazone treatment relieved bone cancer-induced mechanical hyperalgesia in a dose-dependent manner, promoted the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) in spinal cord neurons, and inhibited the activation of the nuclear factor-kappa B (NF-κB)/nod-like receptor protein 3 (NLRP3) inflammatory axis induced by BCP. However, concurrent administration of the PPAR-γ antagonist GW9662 reversed these effects. The results show that rosiglitazone inhibits the NF-κB/NLRP3 inflammation axis by activating PPAR-γ in spinal neurons, thereby alleviating BCP. Therefore, the PPAR-γ/NF-κB/NLRP3 signaling pathway may be a potential target for the treatment of BCP in the future.

scholarly journals Levo-Tetrahydropalmatine Attenuates Bone Cancer Pain by Inhibiting Microglial Cells Activation

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Mao-yin Zhang ◽  
Yue-peng Liu ◽  
Lian-yi Zhang ◽  
Dong-mei Yue ◽  
Dun-yi Qi ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Mechanical Allodynia ◽  
Thermal Hyperalgesia ◽  
Bone Cancer ◽  
Microglial Cells ◽  
Bone Cancer Pain ◽  
Enzyme Linked Immunosorbent Assay ◽  
Analgesic Effects ◽  
Before And After

Objective. The present study is to investigate the analgesic roles of L-THP in rats with bone cancer pain caused by tumor cell implantation (TCI).Methods. Thermal hyperalgesia and mechanical allodynia were measured at different time points before and after operation. L-THP (20, 40, and 60 mg/kg) were administrated intragastrically at early phase of postoperation (before pain appearance) and later phase of postoperation (after pain appearance), respectively. The concentrations of TNF-α, IL-1β, and IL-18 in spinal cord were measured by enzyme-linked immunosorbent assay. Western blot was used to test the activation of astrocytes and microglial cells in spinal cord after TCI treatment.Results. TCI treatment induced significant thermal hyperalgesia and mechanical allodynia. Administration of L-THP at high doses significantly prevented and/or reversed bone cancer-related pain behaviors. Besides, TCI-induced activation of microglial cells and the increased levels of TNF-αand IL-18 were inhibited by L-THP administration. However, L-THP failed to affect TCI-induced astrocytes activation and IL-1βincrease.Conclusion. This study suggests the possible clinical utility of L-THP in the treatment of bone cancer pain. The analgesic effects of L-THP on bone cancer pain maybe underlying the inhibition of microglial cells activation and proinflammatory cytokines increase.

scholarly journals Promotion of bone cancer pain development by decorin is accompanied by modification of excitatory synaptic molecules in the spinal cord

2019 ◽  
Vol 15 ◽  
pp. 174480691986425 ◽  
Author(s):  
Huan Wang ◽  
Xiaohui Li ◽  
Xianqiao Xie ◽  
Haiwen Zhao ◽  
Yan Gao ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Bone Cancer ◽  
Bone Cancer Pain

scholarly journals Transcriptomic analysis of long noncoding RNAs and mRNAs expression profiles in the spinal cord of bone cancer pain rats

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Xinran Hou ◽  
Yingqi Weng ◽  
Qulian Guo ◽  
Zhuofeng Ding ◽  
Jian Wang ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Expression Profiles ◽  
Noncoding Rnas ◽  
Bone Cancer ◽  
Long Noncoding Rnas ◽  
Transcriptomic Analysis ◽  
Bone Cancer Pain

scholarly journals CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord

2014 ◽  
Vol 11 (1) ◽  
pp. 75 ◽  
Author(s):  
Wen Shen ◽  
Xue-Ming Hu ◽  
Yan-Nan Liu ◽  
Yuan Han ◽  
Li-Ping Chen ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Bone Cancer ◽  
Glial Activation ◽  
Bone Cancer Pain ◽  
Rat Spinal Cord

scholarly journals Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway

2017 ◽  
Vol 243 (1) ◽  
pp. 57-65 ◽  
Author(s):  
Li Zhuang ◽  
Ke Li ◽  
Gaowei Wang ◽  
Tao Shou ◽  
Chunlin Gao ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Rat Model ◽  
Mechanical Allodynia ◽  
Antinociceptive Effect ◽  
Thermal Hyperalgesia ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Kinase Pathway

Bone cancer pain (BCP) is a severe type of hyperpathic pain occurring with primary bone tumors or advanced cancers which metastasize to bones. BCP can detrimentally reduce quality of life and presents a challenge to modern medicine. Studies have shown that exogenous H2S may act as a neuroprotectant to protect against some diseases in central nervous system. The preset study aimed to investigate the antinociceptive effect of H2S in BCP. We first measured the changes of serum H2S in patients with BCP and analyzed the relationship between them, then investigated the effect of H2S preconditioning on BCP, and explored the mechanism in rat model. Our results revealed that serum H2S level was negatively correlated with pain scores. In the rat model of BCP, preconditioning with H2S significantly reduced BCP, demonstrated by the decrease of thermal hyperalgesia and mechanical allodynia. The mechanism of H2S preconditioning may involve microglia deactivation and inflammation inhibition in the spinal cord, in which the proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway is activated. Impact statement Bone cancer pain (BCP) significantly decreases the life quality of patients or their life expectancy and causes a severe health burden to the society. However, as the exact mechanism of BCP is still poorly understood, no effective treatment has been developed yet. There are some pain medicines now, but they have some inevitable side effects. Additional therapeutic strategies are urgently needed. First, we revealed that preconditioning with H2S significantly reduced BCP, demonstrated by the decrease of thermal hyperalgesia and mechanical allodynia. Second, the mechanism of H2S preconditioning was elucidated. It may involve microglia deactivation and inflammation inhibition in the spinal cord, in which the proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway is activated. This novel finding may significantly help us to understand the difference between the roles of endogenous H2S and exogenous H2S in the development of BCP and present us a new strategy of pain management.

Sign in / Sign up

Export Citation Format

Share Document